KARYOPHARM THERAPEUTICS INC (KPTI)
Health Care · Oncology biopharmaceuticals / targeted cancer therapeutics · NASDAQ
Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in myelofibrosis and endometrial cancer.
What KARYOPHARM THERAPEUTICS INC does
Karyopharm Therapeutics is a biopharmaceutical company focused on developing and commercializing cancer treatments based on XPO1 (nuclear export) inhibition technology. The company's approved product, XPOVIO (selinexor), is currently marketed in the U.S. for multiple myeloma and other hematologic malignancies. Karyopharm is advancing a clinical pipeline including programs in myelofibrosis, endometrial cancer, and additional multiple myeloma indications, while exploring partnerships to expand XPOVIO's global reach.
Themes: ["XPO1 inhibition / nuclear export inhibitors","Multiple myeloma treatment","Myelofibrosis treatment","Endometrial cancer treatment","Oncology / cancer therapeutics"]
Fundamentals
- Price$10.20 as of 2026-07-09 close
- Market cap$242M as of 2026-07-10
- 1-year return+112.1% as of 2026-07-09 close
- Net margin-129.0% as of 2026-07-10
- Gross margin+96.0% as of 2026-07-10
- ROE-182.4% as of 2026-07-10
- Debt / equity3.78 as of 2026-07-10
- Revenue growth (YoY)+6.3% as of 2026-07-10
- Revenue CAGR (3y)-2.4% SEC XBRL
- Beta0.87 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with negative net margin of -129% and significant cash burn, raising substantial doubt about ability to continue as a going concern","XPOVIO is the only source of product revenue and commercial success depends heavily on expanding sales in multiple myeloma and achieving clinical approval in additional indications","Clinical pipeline advancement and regulatory approval timelines are uncertain; failure to achieve development milestones in myelofibrosis, endometrial cancer, or other programs would impact future revenue and valuation"]
Competitors & peers
- Takeda Pharmaceutical (TAK) — multiple myeloma treatments
- Bristol Myers Squibb (BMY) — oncology and multiple myeloma portfolio
- Celgene (acquired by Bristol Myers Squibb) — multiple myeloma therapies
- Novartis (NVS) — oncology and hematology treatments
- Acceleron Pharma / Merck (MRK) — myelofibrosis treatments (luspatercept, fedratinib)
- Genmab (GMAB) — cancer immunotherapy
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.